Back to search
FDAFDA · Food and drugs·Recall number D-0390-2021

Cefixime for Oral Suspension USP 100 mg/5mL, 50mL HDPE bottles, Rx Only, Manufactured by: Lupin Pharmaceuticals, Inc. Baltimore, Maryland, 21202 United States, Manufactured by: Lupin Limited, Manddeep, 462 046, India, NDC 68180-405-01

Published May 26, 2021 · Recall initiated: April 29, 2021

Summary

FDA records drug Class II recall D-0390-2021, published May 26, 2021 and initiated April 29, 2021. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 3,138 bottles; Lot: Lot #: F900787, Exp. Date 4/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug

What to do

Voluntary: Firm initiated · Letter

Get an email if CEFIXIME has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CEFIXIME
Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
Nationwide within the United States
UPC
0368180423089
Lot
Lot #: F900787, Exp. Date 4/2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Cefixime for Oral Suspension USP 100 mg/5mL, 50mL HDPE bottles, Rx Only, Manufactured by: Lupin Pharmaceuticals, Inc. Baltimore, Maryland, 21202 United States, Manufactured by: Lupin Limited, Manddeep, 462 046, India, NDC 68180-405-01 recalled?

Yes. FDA published recall D-0390-2021 on May 26, 2021. Reported hazard: Subpotent Drug

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CEFIXIME. UPC: 0368180423089.